
RLAY Stock Forecast & Price Target
RLAY Analyst Ratings
Bulls say
Relay Therapeutics Inc. is positioned for a promising trajectory due to its innovative drug candidate RLY-2608, which is expected to enhance the market for PI3Ka inhibitors through its best-in-class efficacy and improved tolerability compared to existing therapies like capivasertib. The positive clinical data surrounding RLY-2608 indicates a potential for rapid market uptake, especially given that capivasertib has already demonstrated significant sales growth, reportedly expanding the market to approximately $700 million. By addressing previously intractable targets in precision oncology and genetic disease through its advanced Dynamo platform, Relay Therapeutics is leveraging cutting-edge technology in its drug discovery process, reinforcing a positive outlook for its pipeline.
Bears say
Relay Therapeutics faces significant challenges due to a dramatic expected decrease in median progression-free survival (mPFS) from 24 months to just 5 months, which raises concerns about the efficacy of its treatments and is likely to impact patient outcomes negatively. Additionally, the commercial launch of inavolisib has fallen short of expectations attributed to safety liabilities related to its mechanism of action, particularly in patients with metabolic issues, which may hinder its market acceptance. This combination of disappointing clinical data and competitive pressures in the oncology market suggests a challenging path ahead for Relay Therapeutics, potentially leading to a negative outlook on its stock performance.
This aggregate rating is based on analysts' research of Relay Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
RLAY Analyst Forecast & Price Prediction
Start investing in RLAY
Order type
Buy in
Order amount
Est. shares
0 shares